depression

(MENAFN - GlobeNewsWire - Nasdaq) NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA ...

(MENAFN - Investor Brand Network)NRx Pharmaceuticals (NASDAQ: NRXP) announced that minutes from a Type C meeting with the U.S. Food and Drug Administration support the agency's willingness to ...

NRx Pharmaceuticals Inc. (NASDAQ:NRXP) shares are surging on Monday following positive developments regarding its New Drug Application for NRX-100 (preservative-free intravenous ketamine).Ketamine is a dissociative anesthetic that has some hallucinogenic effects. It is primarily used in medical and veterinary settings for surgery and pain management, and increasingly for mental health treatment.FDA Signals Openness To Review NRx Pharmaceuticals’ NRX-100 ApplicationThe FDA has confirmed its willi

Understanding what depression is – and what it is not – is often the first step toward relief.

Researchers have discovered a surprising change in how cells produce energy in people with depression. Brain and blood cells in young adults with major depressive disorder produced more energy molecules at rest but had trouble increasing energy production when needed. Scientists believe this imbalance may contribute to symptoms such as fatigue and low motivation. The finding could help pave the way for earlier diagnosis and more personalized treatments.

LONDON & NEW YORK--(BUSINESS WIRE)--Mar 12, 2026--

The below clickable headlines link directly to outside media outlets, which featured UNC School of Medicine faculty starting Friday, March 6, 2026. Continue reading

When choosing the best berberine supplements, we've prioritised high bioavailability, trusted brands and formulations with minimal fillers

Exton, PA, March 10, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights today announced the release of its 2026 Patient Chart DynamixTM: Sickle Cell Disease (US) report, an in-depth analysis of 133 real-world patient charts collected from 86 U.S. hematologist/oncologists offering...

BPL‐003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through the planned early-2029 topline readouts from both parallel Phase 3 pivotal studiesCommercial readiness advancing with scalable treatment model aligned to existing...

The Food and Drug Administration’s top drug regulator, Dr. Tracy Beth Hoeg, is working to hire a researcher and friend who wants the agency to add new warnings to antidepressants about unproven pregnancy risks, The Associated Press has learned.

A newly identified protein may hold the key to preventing diabetic blindness. Researchers discovered that LRG1 triggers the earliest damage in diabetic retinopathy by constricting tiny retinal blood vessels and reducing oxygen supply. In mice, shutting down this protein stopped the damage before it could take hold. The finding could pave the way for treatments that protect vision before symptoms ever begin.